{"nctId":"NCT01585584","briefTitle":"Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment","startDateStruct":{"date":"2012-05"},"conditions":["Hepatitis C"],"count":11,"armGroups":[{"label":"Boceprevir","type":"EXPERIMENTAL","interventionNames":["Drug: Boceprevir"]}],"interventions":[{"name":"Boceprevir","otherNames":["VICTRELIS™","boceprevir capsules, 200 mg","Hepatitis C Virus (HCV) Protease Inhibitor"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects will be eligible for the study if they meet the following inclusion criteria:\n\n  1. 18 years of age or older\n  2. Infected with HCV genotype 3 (mixed genotypes are NOT permitted)\n  3. Have received at least 12 weeks of previous treatment with peginterferon-α + ribavirin\n  4. Detectable serum HCV-RNA\n  5. No significant co-morbid conditions\n  6. Liver biopsy is not necessary\n  7. Cirrhotic patients will be eligible to participate if Child-Pugh class A (maximum 15% of subjects)\n\nExclusion Criteria:\n\n* Subjects will be excluded from participation in this study if the following conditions are present:\n\n  1. Significant comorbidities: uncontrolled psychiatric conditions including severe depression, cardiovascular, respiratory, renal or metabolic conditions, active carcinoma.\n  2. Active substance abuse within the past 12 months\n  3. Co-infection with hepatitis B or HIV\n  4. Decompensated cirrhosis (Child-Pugh class B or C)\n  5. Significant cytopenia - any of the following: platelets \\<80 x 109/L, neutropenia \\<1.2 x 103/L, Hb \\<120 g/l for men or 110 g/l for women\n  6. Lack of informed consent\n  7. Previous null-responders (\\<2 log10 decrease at week 12 with previous PR therapy)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Sustained Virologic Response (SVR) at 24 Weeks Post Treatment","description":"Sustained Virologic Response (SVR) is evaluated 24 weeks after end of treatment and defined as undetectable plasma HCV-RNA at follow up week 24. HCV RNA is measured using Cobas TaqMan.Of the 6 subjects who completed the treatment, 3 obtained SVR at 24 weeks post treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":10},"commonTop":["Insomnia","Anemia","Local injection site reactions","Muscle pain","Chills"]}}}